2024
Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities
Valdez C, Sánchez-Zuno G, Bucala R, Tran T. Macrophage Migration Inhibitory Factor (MIF) and D-Dopachrome Tautomerase (DDT): Pathways to Tumorigenesis and Therapeutic Opportunities. International Journal Of Molecular Sciences 2024, 25: 4849. PMID: 38732068, PMCID: PMC11084905, DOI: 10.3390/ijms25094849.Peer-Reviewed Original ResearchConceptsInhibition of MIFResponse to infectionNon-canonical signaling pathwaysClinical studiesCancer patientsClinical trialsInflammatory cytokinesDriving tumorigenesisClinical explorationCancer typesCancerDual inhibitionTherapeutic targetIn vivoIn vitroSignaling pathwayMIFAntitumor candidateBinding partners
2023
Macrophage migration inhibitory factor (MIF) and its homolog D-dopachrome tautomerase (D-DT) are significant promotors of UVB- but not chemically induced non-melanoma skin cancer
Huth S, Huth L, Heise R, Marquardt Y, Lopopolo L, Piecychna M, Boor P, Fingerle-Rowson G, Kapurniotu A, Yazdi A, Bucala R, Bernhagen J, Baron J. Macrophage migration inhibitory factor (MIF) and its homolog D-dopachrome tautomerase (D-DT) are significant promotors of UVB- but not chemically induced non-melanoma skin cancer. Scientific Reports 2023, 13: 11611. PMID: 37464010, PMCID: PMC10354066, DOI: 10.1038/s41598-023-38748-9.Peer-Reviewed Original ResearchConceptsMacrophage migration inhibitory factorNon-melanoma skin cancerD-DTSkin cancerRecombinant macrophage migration inhibitory factorUVB irradiationAcute UVB irradiationPrevention of photocarcinogenesisMigration inhibitory factorAccumulation of macrophagesAdditive protective effectChronic UVB irradiationDouble knockout micePotential therapeutic targetMacrophage accumulationCommon cancerPathophysiological roleProtective effectSkin tumorsKnockout miceTherapeutic targetInhibitory factorGenetic deletionCytokinesCancer
2006
Immunosuppressive Factors in Cancer
Moss J, Metz C, Bucala R. Immunosuppressive Factors in Cancer. 2006 DOI: 10.1002/3527600906.mcb.200400129.Peer-Reviewed Original ResearchImmunosuppressive factorsTumor cellsHost's antitumor defenseHost immune responseHost immune systemSuccessful cancer therapeuticsCancer patientsAntitumor defenseImmune responseEffective treatmentEvasive mechanismsImmune systemCell surface receptorsCancer therapeuticsSurface receptorsCancerCellsPatientsCytokinesProstaglandinsAntigenMajor obstacleReceptors634: Mice with a Null Mutation For Macrophage Migration Inhibitory Factor Have Lower Stage Tumors in a Mouse Model of Bladder Cancer
Taylor J, Kuchel G, Hegde P, Voznesensky O, Sasso D, Claffey K, Bucala R, Pilbeam C. 634: Mice with a Null Mutation For Macrophage Migration Inhibitory Factor Have Lower Stage Tumors in a Mouse Model of Bladder Cancer. Journal Of Urology 2006, 175: 204. DOI: 10.1016/s0022-5347(18)32880-5.Peer-Reviewed Original Research
2005
1409: Further Evidence for an Association between Macrophage Migration Inhibitory Factor and Prostate Cancer
Meyer-Siegler K, Iczkowski K, Leng L, Bucala R, Vera P. 1409: Further Evidence for an Association between Macrophage Migration Inhibitory Factor and Prostate Cancer. Journal Of Urology 2005, 173: 382. DOI: 10.1016/s0022-5347(18)35543-5.Peer-Reviewed Original Research
2002
Immunosuppresive Factors in Cancer
Bucala R, Metz C. Immunosuppresive Factors in Cancer. 2002, 119-154. DOI: 10.1002/3527600795.ch7.Peer-Reviewed Original Research